Aspiriant LLC reduced its position in Celgene Corporation (NASDAQ:CELG) by 14.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,504 shares of the biopharmaceutical company’s stock after selling 1,744 shares during the quarter. Aspiriant LLC’s holdings in Celgene Corporation were worth $1,364,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Harbour Capital Advisors LLC grew its holdings in shares of Celgene Corporation by 12,913.6% during the second quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after buying an additional 1,575,074 shares during the last quarter. Investec Asset Management LTD purchased a new stake in shares of Celgene Corporation during the first quarter valued at $194,490,000. Clearbridge Investments LLC grew its holdings in shares of Celgene Corporation by 24.1% during the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after buying an additional 892,392 shares during the last quarter. State Street Corp grew its holdings in shares of Celgene Corporation by 2.3% during the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares during the last quarter. Finally, Pioneer Investment Management Inc. grew its holdings in shares of Celgene Corporation by 15.7% during the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after buying an additional 710,584 shares during the last quarter. 79.23% of the stock is currently owned by institutional investors and hedge funds.
Shares of Celgene Corporation (NASDAQ CELG) opened at 98.17 on Friday. Celgene Corporation has a 1-year low of $95.52 and a 1-year high of $147.17. The stock has a market cap of $76.80 billion, a PE ratio of 30.40 and a beta of 1.88. The stock has a 50 day moving average of $139.20 and a 200 day moving average of $130.37.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 68.62%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.58 earnings per share. Equities research analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.
In other news, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last three months, insiders sold 46,233 shares of company stock valued at $6,268,259. Company insiders own 0.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Aspiriant LLC Has $1.36 Million Stake in Celgene Corporation (CELG)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/10/28/celgene-corporation-celg-shares-sold-by-aspiriant-llc.html.
CELG has been the topic of a number of research analyst reports. Vetr lowered shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective on the stock. in a report on Tuesday, August 29th. Leerink Swann reissued a “buy” rating and set a $156.00 price objective on shares of Celgene Corporation in a report on Friday, October 20th. Cantor Fitzgerald reissued a “buy” rating on shares of Celgene Corporation in a report on Monday, August 28th. William Blair reaffirmed an “outperform” rating on shares of Celgene Corporation in a report on Friday, October 20th. Finally, Morgan Stanley lowered their price target on shares of Celgene Corporation from $120.00 to $115.00 and set an “underweight” rating on the stock in a report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $142.07.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.